Results 211 to 220 of about 375,217 (345)

Lifespan Pancreas Morphology for Control Versus Type 2 Diabetes Using AI on Largescale Clinical Imaging

open access: yesClinical Anatomy, EarlyView.
ABSTRACT Understanding how pancreas size and shape change with normal aging is critical for establishing a baseline to detect deviations in type 2 diabetes and other pancreatic disease. We measure pancreas size and shape using morphological measurements from early development through aging (ages 0–90).
Lucas W. Remedios   +13 more
wiley   +1 more source

Polycystic ovary syndrome and abdominal fat: is there a relationship? [PDF]

open access: yesRev Assoc Med Bras (1992), 2023
Macruz CF, Lima SMRR.
europepmc   +1 more source

Grooved Surface of the Obturator Internus Muscle With Two Distinct Adjacent Parts

open access: yesClinical Anatomy, EarlyView.
ABSTRACT The specific anatomical features of the obturator internus, particularly those of its medial surface, remain insufficiently characterized. This study investigated the morphology of the obturator internus muscle by focusing on the shape of its medial surface and potential age‐related changes.
Satoru Muro   +4 more
wiley   +1 more source

Succinic acid-driven gut-fat axis orchestrates abdominal fat deposition in chickens via adipocyte-macrophage crosstalk. [PDF]

open access: yesJ Anim Sci Biotechnol
Chen J   +8 more
europepmc   +1 more source

Lipid Profile Differences in HIV‐Infected Populations With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Systematic Review and Meta‐Analysis

open access: yesChronic Diseases and Translational Medicine, EarlyView.
PRISMA study flow diagram. ABSTRACT Introduction Advances in HIV management have transformed HIV into a chronic condition, resulting in improved prognosis and increased survival among people living with HIV (PLWH). Traditional risk factors for metabolic dysfunction‐associated steatotic liver disease (MASLD)—including dyslipidemia—are prevalent in PLWH.
Yovita Hartantri   +6 more
wiley   +1 more source

Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Fezolinetant is a first‐in‐class, selective, non‐hormonal, neurokinin 3 receptor antagonist that is approved for the treatment of moderate to severe vasomotor symptoms due to menopause. In a phase 2b clinical study (n = 352), nine study participants experienced elevations in serum transaminases exceeding three times the upper limit of normal.
Jace C. Nielsen   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy